Kornimate/medical-research-clean huggingface dataset:
full-avoidance vs. permissive/regulated drinking & outcomes on fibrillation

Conditions: Atrial Fibrillation (AF); Atrial Fibrillation (Paroxysmal)

Summary: the goal of this study is to assess the short-term effects of minimal and moderate drinking on atrial fibrillation (afib) episodes in a real-world population diagnosed with 'come-and-go'/paroxysmal afib. the question it aims to answer is: is there a greater occurrence of afib episodes when participants are allowed to consume alcohol according to random assignment? participants will: * be given daily random assignments to avoid or not to avoid alcohol * wear an adhesive electrocardiographic (ecg) heart monitor * wear a wrist-worn fitness tracker * wear an anklet transdermal alcohol monitor * wear an adhesive glucose monitor * complete morning and evening surveys daily participants may be compensated up to $50 for full completion of the study. this study can be done in-person or remote.

this study is a case-crossover randomized trial, where each participant will be instructed to avoid or not avoid drinking alcohol on randomly assigned days during a 14-day monitoring period. participants will also wear an external ecg monitor, an alcohol monitor, a continuous glucose monitor, and a fitness tracker for up to two weeks while utilizing a mobile application to receive daily instructions/reminders on drinking and short surveys. the investigators will compare participant self-report of alcohol consumption, glucose monitoring, fitness levels, sleep health, and heart rhythm data in order to better understand the immediate relationship between drinking alcohol and heart rhythm. a total of 100 participants will be enrolled.

Eligibility criteria:
inclusion criteria * comfortable reading and writing in english * have a smartphone and willing and able to use the eureka mobile application * currently diagnosed with paroxysmal afib without a plan to change their afib management during the two-week monitoring period * at least one episode of afib in the past month or, in the judgement of a healthcare provider, could potentially have one episode of af in the next month * drank alcohol at least 1 day/week on average in the past month * willing and able to be randomly assigned daily to avoid or not avoid drinking alcohol over a 2-week period * willing and able to provide written informed consent exclusion criteria * only post-operative afib * greater than 40% ventricular pacing * history of alcohol addiction or abuse determined by self-reported history or audit-c score * intolerance to alcohol * history of liver disease * currently incarcerated * currently pregnant or trying to get pregnant

Keywords: alcohol drinking mediterranean drinking pattern atrial fibrillation afib af heart rhythm
comparison of the efficacy of irrigation with epinephrine or tranexamic acid on visual clarity

Conditions: Rotator Cuff Tears

Summary: the primary aim of this report is to determine whether there is a difference between epinephrine and tranexamic acid in providing visual clarity during arthroscopic rotator cuff tear repair.


Eligibility criteria:
inclusion criteria: * • age \> 18 years * american society of anesthesiologist physical status classification system : 1-2 * undergoing a full arthroscopic double-row repair due to full-thickness cuff tear * being willing to participate the study exclusion criteria: * • age \< 18 years * american society of anesthesiologist physical status classification system ≥3 * concomitant cardiac diseases * concomitant bleeding disorder or coagulopathy * diabetes mellitus * being pregnant * use of contraceptive pills * a history of previous shoulder surgery * uncontrolled hypertension during the operation (\>180/110 mm hg) * unrepairable rotator cuff tears * being unwilling to participate the study

Keywords: shoulder arthroscopy irrigation epinephrine image quality tranexamic acid cuff tear repair visual clarity
examining the efficacy of a mobile therapy for children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the purpose of this research is to study the effects of a novel artificial intelligence (ai) tool for automatic facial expression recognition that runs on google glass through an android app to deliver social emotion cues to children with autism during social interactions. this novel device will use a camera, microphone, head motion tracker to analyze the behavior of the subject during interactions with other people. the system is designed to give participants non-interruptive social cues in real-time and will record social responses that can later be used to help aid behavioral therapy. it is hypothesized that the system's ability to provide continuous behavioral therapy during social interactions will enable faster gains in social skills.


Eligibility criteria:
inclusion criteria: 1. the child has been diagnosed professionally with asd 2. the child is currently receiving aba therapy at least twice per week at home. 3. the child's family is willing to drive to stanford university for up to 4 study appointments. exclusion criteria: 1. the child scores less than 15 on the social communication questionnaire 2. the child's family does not speak english

Keywords: mobile health, autism, asd, mobile therapy, digital, wearable computing, technology
interruption of tnfinhibitors and endothelial function

Conditions: Reumatoid Arthritis; Cardiovascular Diseases

Summary: patients with rheumatoid arthritis (ra) have an increased risk of cardiovascular events. this increased risk is thought to be driven by inflammation-induced endothelial dysfunction, an initial step in atherogenesis. treatment with tnfalpha inhibitors (tnfi) improve endothelial function in patients with ra. discontinuation of tnfi could therefore worsen endothelial function even in the absence of recurrence of systemic inflammation or reactivation of arthritis. if stopping tnfi results in worsening of endothelial function this would strongly suggest a higher cardiovascular risk in association with tnfi-wthdrawal

patients with rheumatoid arthritis (ra) have an increased risk of cardiovascular events. this increased risk is thought to be driven by inflammation-induced endothelial dysfunction, an initial step in atherogenesis. both systemic as well as local (intra-arterial) treatment with anti-tnf-antibody therapy improves endothelial function in patients with vasculitis or ra as reflected by the vasodilator response to intra-arterially infused acetylcholine. also other vascular functions that are (at least partially) endothelium-dependent such as flow-mediated dilation of the brachial artery and pulse wave velocity are improved when active ra patients are being treated with methotrexate plus tnfi, i.e. infliximab or etanercept. ( therefore one may hypothesize that when tnfi therapy is stopped, endothelial function may worsen even in the absence of recurrence of systemic inflammation or reactivation of arthritis. endothelial function tests are a marker of long-term cardiovascular mortality. if stopping tnfi results in worsening of endothelial function this would strongly suggest a higher cardiovascular risk in association with tnfi-wthdrawal. these findings would indicate an important drawback for stopping tnfi in ra patients. to date it is unclear whether the worsening of endothelial function occurs within half a year following the (successful) cessation of tnfi, whether this decline occurs simultaneously, or prior to ra exacerbation and whether this deterioration process is delayed by additional use of statin and/or acei. to improve cardiovascular prognosis in ra significantly it is important to increase our knowledge regarding these processes.

Eligibility criteria:
inclusion criteria: * informed consent for poeet trial and this additional study * on stable medication (except for tnfi-therapy) exclusion criteria: * uncontrolled hypertension (rr \> 140/90 mmhg average of three measurements at screening after 5 minutes of supine rest) * diabetes mellitus * heart failure or any other cardiovascular disease that is expected to induce changes in cardiovascular medication during the study period. * expected to start or change medication that can alter endothelial function (lipid lowering drugs, blood pressure lowering drugs, nsaids, immunosuppressive therapy other than tnfi drugs)
challenge dose of hepatitis b vaccine in subjects who previously received engerix™-b vaccine

Conditions: Hepatitis B

Summary: to evaluate the response to an additional dose (challenge dose) of hepatitis b vaccine, when given to subjects who had received primary vaccination of engerix™-b vaccine approximately 72-78 months ago. this protocol posting deals with objectives \& outcome measures of the challenge phase. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol. * a male or female who had received complete primary vaccination course of hepatitis b vaccine in the primary study * written informed consent obtained from the subject and/or parent/guardian of the subject. * healthy subjects as established by medical history and clinical examination before entering into the study. * if the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after the hepatitis b challenge dose. exclusion criteria: * use of any investigational/non-registered drug or vaccine other than the study vaccine within 30 days preceding the hepatitis b vaccine challenge dose or planned use during the study period. * chronic administration (more than 14 days) of immunosuppressants other immune-modifying drugs within six months prior to the hepatitis b vaccine challenge dose. * planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before the hepatitis b vaccine challenge dose and ending 30 days after. * subjects who received an additional dose of hepatitis b vaccine outside the context of the study between the primary vaccination course and the hepatitis b challenge vaccination visit. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * acute disease at the time of enrolment. * acute or chronic, clinically significant hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * administration of immunoglobulins and/or any blood products within the three months preceding the hepatitis b vaccine challenge dose or planned administration during the study period (one month). * pregnant or lactating female. * female planning to become pregnant or planning to discontinue contraceptive precautions.

Keywords: hepatitis b persistence challenge dose
digital therapeutic development of virtual cognitive-affective training for opioid use disorder

Conditions: Opioid-use Disorder

Summary: this is a phase 1 trial that aims to establish the safety of more-vr, as well as to collect feasibility, usability, and engagement data, for patients receiving medications for opioid use disorder (moud).


Eligibility criteria:
inclusion criteria: * age 18 or older * dsm-5 opioid use disorder diagnosis * treated with medications for opioid use disorder (moud) exclusion criteria: * mindfulness intervention experience (mbsr, mbrp) * active psychosis or high risk of suicidality * cognitive impairment (per self-report or report by clinician) * unwilling or unable to remain in moud treatment for duration of study
application and clinical evaluation of longitudinal chromatic aberration technique in ophthalmology

Conditions: Longitudinal Chromatic Aberration; Blue Light Defocus Manipulation

Summary: our study aims to delve into the effects of shifting the focal point of blue light from video or text displayed on a terminal screen forward on the axial length of the eye, ocular blood flow, visual fatigue, and visual function, that is, its relationship with video display terminal (vdt) syndrome and myopia. by examining the decoding ability of the adult subjects' retina to the clarity of the signal, we will attempt to develop a novel, non-invasive strategy to curb the elongation of the eyeball associated with myopia. concurrently, we will also focus on the pathophysiological mechanisms underlying vdt syndrome and explore its potential link to the progression of myopia, providing new scientific evidence for the prevention and treatment of this ocular condition. this research is expected to provide robust support for addressing the global issue of myopia and the health challenges posed by vdt syndrome. ultimately, by integrating global eye health issues with the challenges brought about by vdt syndrome, we will propose intervention and prevention strategies, offering new insights for the advancement of ophthalmology and public health sectors, thereby promoting visual acuity and ocular health for the population.


Eligibility criteria:
inclusion criteria: 1. adult population, regardless of gender 2. refractive error is less than or equal to -2.5d and both eyes achieve corrected visual acuity of 0.8 or higher. 3. normal intraocular pressure with no organic pathology. 4. no apparent symptoms of dry eye. 5. willing to cooperate to complete all the tests. 6. voluntarily signing the informed consent form. exclusion criteria: 1. individuals with strabismus and amblyopia exist. 2. suffering from congenital eye conditions such as congenital cataracts or congenital retinal diseases. 3. those who have undergone intraocular surgery (such as cataract removal, intraocular lens implantation, etc.). 4. individuals with refractive media opacity (such as corneal lesions, lens opacity, etc.). 5. abnormal intraocular pressure (iop) (iop \ 21 mmhg, or a bilateral iop difference of ≥5 mmhg). 6. only one eye meets the inclusion criteria. 7. active corneal infections such as bacterial, fungal, viral, or other acute or chronic anterior segment inflammations. 8. currently using medications that may lead to dry eye or affect vision and corneal curvature. 9. other ocular conditions, such as dacryocystitis, eyelid disorders and abnormalities, abnormal intraocular pressure, and glaucoma. 10. unable to undergo regular eye examinations.

Keywords: longitudinal chromatic aberration reading efficiency visual function visual fatigue fundus blood flow axial length total refraction difference value
rocky mountain alzheimer's disease center longitudinal biomarker and clinical phenotyping study

Conditions: Alzheimer Disease; Down Syndrome; Mild Cognitive Impairment

Summary: this study plans to establish a large bank of blood, cerebral spinal fluid (csf), imaging, and clinical data. these data and samples will be used for future research into the causes of alzheimer's disease (ad), down syndrome (ds) and other diseases that cause thinking and memory problems. this future research will also study how treatments for these diseases work. this research may help develop new treatments for some diseases of the nervous system and help understand these diseases better.


Eligibility criteria:
inclusion criteria: 1. persons with age-related mci or ad according to clinical diagnosis, consistent with nia-aa diagnostic criteria 2. community-dwelling controls, age \> 60 years 3. ability to complete baseline assessments 4. has an informant (study partner) available to complete functional interviews/survey measures annually exclusion criteria: * presence of concomitant medical, neurological, or psychiatric illness or condition that in the opinion of the investigators would confound interpretation of study results. these include: korsakoff encephalopathy; active substance abuse; hepatitis c; opportunistic brain infection; brain tumor; active neoplastic disease (skin tumors other than melanoma are not exclusionary; participants with stable prostate cancer may be included at the discretion of the project director); multiple sclerosis; history of clinically significant stroke; current evidence or history in the past 2 years of focal brain lesion, head injury with loss of consciousness, or dsm-v criteria for any major psychiatric disorder, including psychosis, major depression, bipolar disorder, alcohol or substance abuse; blindness, deafness or any other disability which may prevent the participant from participating or cooperating in the protocol. * presence of contraindication for mri scan
dietary maneuvers to reduce production of colon-derived uremic solutes

Conditions: Kidney Failure, Chronic

Summary: this study will assess whether dietary fiber supplements can reduce the production of chemicals which are produced by colon bacteria and normally excreted from the body by the kidney, but build up in the body in patients on hemodialysis.

the study procedures will consist of: * taking a dietary supplement containing either fiber or starch (starch serves as a control for fiber) for six weeks. the fiber dose initially employed will be 30 g/day of high amylose corn and the control starch dose employed will be 30 g/day of waxy corn starch. supplements which come in dry powder form will be mixed in liquid or food for consumption. * filling out a food record and a quality of life questionnaire * keeping a diary of any gi symptoms * collecting samples of blood, spent dialysate, urine(if the patient still makes urine) and stool.

Eligibility criteria:
inclusion criteria: * stable dialysis patients able to provide consent. exclusion criteria:-- known g.i. disease * use of antibiotics for the last two month or expected antibiotic use * recent hospitalization or other event resulting in instability of food intake
evaluating the safety and efficacy of carbocisteine in the treatment of nonalcoholic fatty liver disease patients

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: nonalcoholic fatty liver disease (nafld) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. nafld is characterized by lipid accumulation in the liver not attributed to other causes. lifestyle interventions, including dietary modification and exercise, remain the cornerstone of nafld treatment. pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven nash and fibrosis.


Eligibility criteria:
inclusion criteria: * either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography exclusion criteria: * pregnant and/or lactating women * excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) * other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. * patients suffering from chronic kidney disease, and hyper/hypoparathyroidism * hypersensitivity to carbocistiene.
a dose-finding study of ro4998452 in patients with diabetes mellitus

Conditions: Diabetes Mellitus Type 2

Summary: this 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of ro4998452 compared to placebo in patients with type 2 diabetes mellitus. patients will be randomized to one of 6 groups to receive ro4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.the anticipated time on study treatment is \<=3 months


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * type 2 diabetes, diagnosed for \>=3 months; * either treated with diet, exercise and stable metformin, or with diet and exercise alone. exclusion criteria: * type 1 diabetes mellitus; * currently or within 2 months prior to screening treated with an oral or injectable anti-diabetic agent except stable doses of metformin; * currently or within 6 months prior to screening treated with any ppargamma agonist; * uncontrolled hypertension; * significant pre-diagnosed diabetic complications requiring treatment.
electronic linkage for inflammatory bowel disease to deliver joint access to health reports

Conditions: Inflammatory Bowel Diseases

Summary: this study evaluated the extent to which a shared health record facilitated better communication, increase individual responsibility for health care and reduce demand for health resources. the study made individualised reports available to patients and general practitioners and gave much more detail about participants chronic disease and treatments, and evaluated its effectiveness in a randomised controlled feasibility trial. one third of patients received care as usual, two thirds of patients received the intervention.

chronic illness is a major cause of health problems. self-management programmes can improve care and reduce healthcare resource use, but rely on well educated patients who are able to take responsibility for their care, have effective communication with health care providers, and easy access to appropriately triaged services. this study utilised inflammatory bowel disease as an exemplar of chronic disease management. to inform the intervention the investigators held a focus group with patients who told the investigators about their concerns relating to education, care planning and communication about their condition. the participants expressed a preference for individualised information about their care, and plans of what to do if symptoms increase. the investigators departmental electronic patient record (genecis), was extended to provide personalised, educationally enriched information to each participant about their inflammatory bowel disease. the investigators customised genecis to develop output reports i.e.: "my history", "my plan" and "my update", that attach specific educational information to the detailed, structured clinical data held on the system, and shared this with participants and their general practitioner.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of inflammatory bowel disease, specifically ulcerative colitis or crohn's disease. 2. aged 18 to 90 years. 3. under the care of consultant gastroenterologists. 4. patient registered with collaborating general practitioner practice. exclusion criteria: a. participants who are unable to comprehend the study.

Keywords: electronic health records health records personal